NasdaqCM:SLSBiotechs
A Look At SELLAS Life Sciences Group (SLS) Valuation After SLS009 Data And New Equity Offering Plans
SELLAS Life Sciences Group (SLS) is drawing attention after releasing preclinical data on its CDK9 inhibitor SLS009 in acute myeloid leukemia and filing both a universal shelf registration and a US$150 million at-the-market equity offering.
See our latest analysis for SELLAS Life Sciences Group.
Those preclinical SLS009 data and the fresh shelf and at the market filing are landing after a sharp run, with the 1 year total shareholder return near 3x and a 52.09% 90 day share price return, even...